MART-1 + Tyrosinase + SOX10
Prediluted Antibody Cocktail
901-3216-042618

VP Echelon™ Series
Catalog Number: AVI 3216 G
Description: 6.0 ml, prediluted
Dilution: Ready-to-use

Intended Use:
For In Vitro Diagnostic Use
MART-1 + Tyrosinase + SOX10 is a cocktail of mouse monoclonal antibodies that is intended for laboratory use in the qualitative identification of MART-1, Tyrosinase and SOX10 proteins by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient’s clinical history and other diagnostic tests by a qualified pathologist.

Summary and Explanation:
MART-1 recognizes a protein of 18 kDa, identified at MART-1 (Melanoma Antigen Recognized by T cells 1). MART-1 is a useful addition to melanoma panels as it is specific for melanocytic lesions (1-3). Studies have shown that MART-1 is more sensitive than HMB45 when labeling metastatic melanomas (3). Tyrosinase is a key enzyme involved in the initial stages of melanin biosynthesis. Studies have shown Tyrosinase to be a more sensitive marker when compared to HMB45 and MART-1. It has also been shown to label a higher percentage of desmoplastic melanomas than HMB45 (1). The combination of MART-1 and Tyrosinase aids in identifying metastatic melanoma in sentinel lymph nodes (2).

The transcription factor SRY-related HMG-Box gene 10 (SOX10) plays an important role in neural crest, peripheral nervous system, and melanocytic cell development (4-8). SOX10 is widely expressed in normal human tissues including melanocytes and breast tissue. SOX10 is also an important marker in malignant tumors such as melanoma, breast carcinoma, gliomas, and benign tumors such as schwannomas (4-6). More importantly, SOX10 has been shown to be expressed in the vast majority of desmoplastic and spindle cell melanomas and has also been shown to be expressed in 100% of nevi (4, 5). SOX10 is also less likely than S100 to be expressed by background fibroblasts and histiocytcs within scars, and thus SOX10 may be superior to S100 in these types of cases (6).

The combination of SOX10 with MART-1 and/or Tyrosinase has been shown to stain a higher percentage of melanomas in lymph nodes and in metastatic melanomas compared to S100. It has also been shown to be more specific than S100, considering that S100 stains dendritic processes in lymph node while SOX10, MART-1 and Tyrosinase are negative (7, 8). The cocktail of SOX10, MART-1 and Tyrosinase may be suitable for tumors of unknown origin or in differential diagnosis of melanoma and its mimics. PATENT PENDING.

Principle of Procedure:
Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, an enzyme labeled polymer is added to bind to the primary antibody. The detection of the bound antibody is evidenced by a colorimetric reaction.

Reagent Provided:
MART-1 + Tyrosinase + SOX10 is provided as a prediluted antibody cocktail of anti-MART-1, anti-Tyrosinase and anti-SOX10 antibodies in buffer with carrier protein and preservative.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>anti-MART-1</th>
<th>anti-Tyrosinase</th>
<th>anti-SOX10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clone</td>
<td>M2-9E3</td>
<td>T311</td>
<td>BC34</td>
</tr>
<tr>
<td>Source</td>
<td>Mouse monoclonal</td>
<td>Mouse monoclonal</td>
<td>Mouse monoclonal</td>
</tr>
<tr>
<td>Isotype</td>
<td>IgG2b</td>
<td>IgG2a</td>
<td>IgG1</td>
</tr>
<tr>
<td>Antigen</td>
<td>MART-1</td>
<td>Tyrosinase</td>
<td>SOX10</td>
</tr>
<tr>
<td>Cellular Localization</td>
<td>Cytoplasmic</td>
<td>Cytoplasmic</td>
<td>Nuclear</td>
</tr>
<tr>
<td>Staining</td>
<td>Brown (DAB)</td>
<td>Brown (DAB)</td>
<td>Brown (DAB)</td>
</tr>
</tbody>
</table>

Storage and Stability:
Store at 2°C to 8°C. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user.

Known Applications:
Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Species Reactivity: Human; others not tested

Positive Tissue Control: Melanoma

Protocol Recommendations (Ventana BenchMark ULTRA Slide Staining System):
Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:
- Using ultraView:
  Template/Detection: ultraView DAB
  Pretreatment Protocol: CC1 Standard
  Primary Antibody: 32 minutes, 37°C
- Using OptiView:
  Template/Detection: OptiView DAB IHC
  Pretreatment Protocol: CC1 32 minutes
  Peroxidase: Pre Primary Peroxidase Inhibitor
  Primary Antibody: 16 minutes, 36°C

Limitations:
The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist.

Bioscare Medical
69 Berry Drive
Pacheco, CA 94553
USA
Tel: 800-799-9499  |  www.biocare.net  |  Fax: 925-503-8080

EC REP EMERGO EUROPE
Prinsessegracht 20
2514 AP The Hague
The Netherlands
Rev: 062117
Limitations Cont’d:
negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.

Quality Control:

Precautions:
1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (9)
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (10)
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The SDS is available upon request and is located at http://biocare.net.

Troubleshooting:
Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

References:

References Cont’d:

VP Echelon Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare's antibodies by Ventana Medical Systems, Inc. Biocare and Ventana are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.